Alpelisib is an oral alpha-specific PI3K inhibitor administred in combination with fulvestrant for the treatment of postmenopausal women with hormone receptors positive and HER2 negative, PIK3CA-mutated, advanced or metastatic BC with progression after endocrine therapy [9]. The gene discussed is PIK3CA; the disease is breast cancer.